

CORRECTION**Long-term Follow-up and Safety of Patients after an Upfront Therapy with Letrozole for Early Breast Cancer in Routine Clinical Care – The PreFace Study**

Carolin C. Hack, Nicolai Maass, Bahriye Aktas et al.

Geburtsh Frauenheilk 2024; 84: 185–195

10.1055/a-2238-3153

published online: 2024-02-08

In the above-mentioned article the co-author Naiba Nabieva was added. The following statement was added to the conflict of interest: N.N. is currently an employee of Novartis and has received travel support from Novartis and TEVA in the past. This was corrected in the online version on 29.4.2024.